ACLX vs. APGE, SWTX, IMCR, IOVA, IBRX, CGON, DNLI, VCEL, BEAM, and KYMR
Should you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Apogee Therapeutics (APGE), SpringWorks Therapeutics (SWTX), Immunocore (IMCR), Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX), CG Oncology (CGON), Denali Therapeutics (DNLI), Vericel (VCEL), Beam Therapeutics (BEAM), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.
Arcellx presently has a consensus price target of $75.64, suggesting a potential upside of 43.20%. Apogee Therapeutics has a consensus price target of $71.83, suggesting a potential upside of 54.35%. Given Apogee Therapeutics' higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Arcellx.
96.0% of Arcellx shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 6.2% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Arcellx had 6 more articles in the media than Apogee Therapeutics. MarketBeat recorded 8 mentions for Arcellx and 2 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.59 beat Arcellx's score of 0.57 indicating that Apogee Therapeutics is being referred to more favorably in the news media.
Arcellx has higher revenue and earnings than Apogee Therapeutics.
Arcellx received 27 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 74.55% of users gave Arcellx an outperform vote.
Apogee Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -64.08%. Apogee Therapeutics' return on equity of 0.00% beat Arcellx's return on equity.
Summary
Arcellx beats Apogee Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Arcellx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
